← Leaderboards
William H. Peranteau
Children'S Hosp Of Philadelphia
$11,466,157
Attributed
$11,466,157
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $8.2M · FY2019–25$10M$7.5M$5M$2.5M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$29,022,231 · 5
By mechanism
U19$21,501,199 · 2
R01$4,881,032 · 2
DP2$2,640,000 · 1
Top collaborators
- Kiran Musunuru5 shared
Others in their field
Other Emerging Leaders on “Postnatal”
- Evan Z Macosko · Broad Institute, Inc.$27,107,011
- Ellen Gould Chadwick · Harvard University D/B/A Harvard School Of Public Health$22,076,082
- Tomasz Nowakowski · University Of California, San Francisco$9,071,439
- Akhgar Ghassabian · New York University School Of Medicine$6,877,963
- Ryan H Bogdan · Washington University$6,539,982
- Nobuyuki Ishibashi · Children'S Research Institute$6,226,701
Research focus
PostnatalIn UteroIn VivoGenesFetalMutationHepatocytePrenatalLifeLiverBirthAdenineMetabolicGuide RnaOrganLipid NanoparticleMorbidity - Disease RateGenetic DiseasesClustered Regularly Interspaced Short Palindromic RepeatsMortalityCrispr/Cas TechnologyPhenotypeTyrosinemiasPharmaceutical Preparations
Grant awards (17)
Postnatal and Prenatal Therapeutic Base Editing for Metabolic Diseases$5,059,052
U19 · FY2025 · NS · contact PI
PROJECT 2: HEREDITARY TYROSINEMIA TYPE 1 (HT1)$1,244,979
U19 · FY2025 · NS · contact PI
Guide RNA manufacturing capabilities for platform in vivo base editing therapies for metabolic liver diseases$1,000,000
U19 · FY2025 · NS · contact PI
Replication study of in vivo postnatal gene editing for metabolic liver disease in the nonhuman primate model$29,667
U19 · FY2025 · NS · contact PI
Postnatal and Prenatal Therapeutic Base Editing for Metabolic Diseases$5,051,652
U19 · FY2024 · NS · contact PI
PROJECT 2: HEREDITARY TYROSINEMIA TYPE 1 (HT1)$1,630,863
U19 · FY2024 · NS · contact PI
In utero gene editing to cure a metabolic liver disease$705,491
R01 · FY2024 · DK · contact PI
Postnatal and Prenatal Therapeutic Base Editing for Metabolic Diseases$6,415,703
U19 · FY2023 · NS · contact PI
PROJECT 2: HEREDITARY TYROSINEMIA TYPE 1 (HT1)$1,069,283
U19 · FY2023 · NS · contact PI
In utero gene editing to cure a metabolic liver disease$737,418
R01 · FY2023 · DK · contact PI
In utero gene editing to cure a metabolic liver disease$738,367
R01 · FY2022 · DK · contact PI
Prenatal pulmonary cell gene editing to cure monogenic lung diseases$394,306
R01 · FY2022 · HL · contact PI
In utero gene editing to cure a metabolic liver disease$737,588
R01 · FY2021 · DK · contact PI
Prenatal pulmonary cell gene editing to cure monogenic lung diseases$397,856
R01 · FY2021 · HL · contact PI
In utero gene editing to cure a metabolic liver disease$760,313
R01 · FY2020 · DK · contact PI
Prenatal pulmonary cell gene editing to cure monogenic lung diseases$409,693
R01 · FY2020 · HL · contact PI
In utero CRISPR-mediated gene editing to cure congenital monogenic disorders$2,640,000
DP2 · FY2019 · HL · contact PI